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A b s t r a c t  
Fast-disintegrating tablet drug delivery is gaining an importance for drug delivery technology 
especially for geriatric and pediatric patient because of swallowing difficulties.   In certain diseases 
such as hypertension and angina pectoris therapy, taking a fast pharmacological response is of 
important criteria. Thus, the aim of the present work was to prepare a novel fast disintegrating 
Bisoprolol Hemifumarate (BH) tablet formulation for sublingual administration based on the use of 2-
hydroxypropyl-βcyclodextrin (HP-βCD) which forms an inclusion complex with (BH) to improve the 
permeability of the drug to sublingual membrane, in addition to mask the taste of the drug through 
the inclusion complex.  Attempts have been made to prepare fast disintegrating tablets of (BH) using 
superdistintegrants like crosscarmellose sodium and crospovidone in concentration of (5%). Eight 
different formulae (B1-B8) with variable tablet excipients were prepared by direct compression 
method using different mucoadhesive polymers such as chitosan and polyethylene glycol 6000 at 
different concentration (3% and 6%) for reduction the flushing action of saliva and to provide enough 
contact time for drug to be absorbed. The tablets were evaluated for the weight variation, hardness, 
friability, wetting time, disintegration time and dissolution study. The formulae B2 and B7 possessed 
the lowest disintegration time due to the presence of the high concentration of chitosan, which has 
some disintegration action, thus were subjected to a pharmacokinetic study using human volunteers. 
The bioavailability of B2 was significantly higher than that of the reference (Concor®) (p > 0.05).  
Thus, the present investigations suggest that (BH) sublingual tablets allowed the rapid tablet 
disintegration, improved bioavailability and effective in emergency treatment of anginal pain and 
hypertension.  





In recent years, sublingual oral drug formulations have been 
developed to overcome the problems related to swallowing 
difficulties and produces faster onset of action than orally ingested 
tablets [1].  For these formulae, small volume of saliva is usually 
sufficient to result in tablet disintegration in the oral cavity; the 
medication then is absorbed partially or entirely into systemic 
circulation from blood vessels in the sublingual mucosa [2].  
Bisoprolol hemifumarate is a highly beta1-selective beta-
adrenoceptor antagonist that blocks catecholamine stimulation of 
β1-adrenergic receptors in the heart and vascular smooth muscle 
that result  in a reduction of heart rate, cardiac output and 
depresses plasma renin levels[3].  This effect may used to reduce 
workload on the heart and hence oxygen demands, so that the 
drug is indicated for treatment of angina pectoris, arrhythmias and 
hypertension[4]. BH is dose dependently absorbed after oral 
administration with low molecular weight and good water 
solubility, so it is suitable candidate for sublingual dosage form. 
Cyclodextrins are frequently used to enhance the bioavailability  
by increasing the drug availability at the surface of biological 
barrier [5]. Cyclodextrins have also beneficial in reducing gastric 
irritation [6] and masking unpleasant tastes or odors [7].  On the 
European market, the sublingual tablets with nicotine complexed 
with β-CD (Nicorette Microtab) are available, which offer fast 
absorption, without unpleasant taste and local mucosa irritation[8]. 
Various techniques can be used to formulate rapidly disintegrating 
tablets; direct compression is one of these techniques which 
requires incorporation of highly water soluble excipients to 
achieve fast tablet disintegration[9]. The purpose of this study was 
to produce sublingual tablets of  (BH) for treatment of 
hypertensive patients and, those who are suffering from angina 
pectoris, especially for elderly in addition, of enhancing the 
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permeability of the drug through comlexation with HP-β-CD. In-
vivo study was done using six male volunteers to compare the 
pharmacokinetics of the prepared formulae with the reference 
(Concor ® tablets).  
Materials and Methods 
Materials  
Bisoprolol hemifumarate (Merck-Barcelona, Spain); 2-Hydroxy 
propyl-ß-cyclodextrin (chemical Co., Milwaukee, WI, USA); 
Polyethylene glycols 6000  (Morgan pharmaceutical Co., Egypt); 
Chitosan high molecular weight (Sigma, St.Louis, USA); Aerosil 
200: Colloidal silicon dioxide (Degussa-Huls Ltd., Frankfurt, 
Germany); Crospovidone  : Cross linked polyvinyl pyrrolidine 
(Fluka, Germany); Crosscarmellose sodium (FMC corporation, 
Philadelphia ,USA); Magnesium stearate, (Prolabo, France); 
Granular mannitol (Sigma, St.Louis, USA). 
Preparation of solid complex 
(BH) and HP-β-CD were weighed accurately at a 1:1 molar ratio 
and mixed by trituration in a mortar to prepare the physical 
mixture, while the inclusion complex was prepared by kneading 
method [10].  The required amounts of (BH) and HP-β-CD were 
accurately weighed and transferred to a mortar then triturated with 
minimum volume of ethanol-water (50:50, v/v) solution. The slurry 
obtained was kneaded for 30 minutes and then dried under 
vacuum at room temperature in presence of calcium chloride as a 
dehydrating agent. 
Physicochemical characterization of BH- HP-β-CD 
binary solid systems 
Differential scanning calorimetry (DSC) 
DSC analysis was performed using DSC (Model DT-60, 
Shimadzu). Samples (3ă4 mg) were heated in open aluminum 
pans at a rate of 10ĈC/min in a 0ă400ĈC temperature range under 
a nitrogen steam. The instrument was calibrated using indium 
(melting point, 156.61 ĈC; enthalpy of fusion, 28.71 J gă1). DSC 
studies were performed for (BH) powder, HP-β-CD polymer, the 
physical mixture (1:1) and the prepared inclusion complex. 
Fourier transform-infrared (FT-IR) spectroscopy 
The FTIR spectra were recorded using a Bruker FTIR 
spectrophotometer according to the KBr disc technique. The FTIR 
measurements were performed in the scanning range of 4000 - 
400 cm-1 at ambient temperature. 




Preparation of tablet 
Sublingual tablets of (BH) was prepared according to table no.1. 
All the excipients except magnesium stearate and Aerosil 200 
were mixed uniformly followed by addition of magnesium stearate 
and aerosil. Tablets were compressed with single flatăfaced 
punch (8mm), Erweka type, GmbH, Germany.  The total weight of 
the formula was maintained at 100mg. 
Evaluation of tablets 
All the tablets were evaluated for different parameters; uniformity 
of weight, diameter and thickness, hardness, friability, 
disintegration time, wetting time, drug content and in vitro 
dissolution study. 
Uniformity of weight: Twenty tablets were randomly selected from 
each batch individually weighed, the average weight and standard 
deviation of 20 tablets was calculated  
Hardness: For each formula, the hardness of five tablets was 
determined using the Monsanto hardness tester (Cadmach). 
Friability: Twenty tablets were weight and placed in the Roche 
friabilator and apparatus was rotated at 25 rpm for 4min. after 
revolution the tablets were dusted and weighed. 
Disintegration test: the tablets were inserted in each of the six 
cells of the  USP disintegration tester apparatus( Hanson 
Research ,USA) ; In this experiment simulated saliva fluid (SSF) 
pH=6.75 kept at 37 μ 0.5ĈC  was used as disintegration  medium  
at constant frequency of 30μ2 cycles/min. Disintegration time was 
that at which all tablets were de-aggregated leaving no residue on 
the basket [11, 12]  
Wetting time: A piece of tissue paper (12 cm X 10.75 cm) folded 
twice was placed in a small Petri dish (ID = 6.5 cm) containing 6 
ml of SorensonÊs buffer pH 6.8. A tablet was put on the paper, and 
the time for complete wetting was measured. This experiment 
mimics the action of saliva in contact with the tablet [13]. 
 
Table no. 1: Formulation of fast disintegrating Sublingual tablet of 
Bisoprolol    hemifumarate 
 
Formulation B1 B2 B3 B4 B5 B6 B7 B8 
Bisoprolol 
hemifumarate 
5 5 5 5 5 5 5 5 
HP-β-CD 21 21 21 21 21 21 21 21 
Chitosan 3 6 - - - - 6 3 
PEG6000 - - 3 6 3 6 - - 
Crospovidone - - - - 5 5 5 5 
Crosscarmellose 
sodium 
5 5 5 5 - - - - 
 
  * All formulae contained, 0.5mg Magnesium stearate, 1mg 
Aerosil 200 , 0.5mg  Mint flavor 
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  * All formulae contained 21 mg of HP- CD to achieve (1:1) molar 
ratio of the complex 
  * Total tablet weight to100 mg (using granular mannitol as 
diluent and serve as sweetener) 
 
Determination of tablets content uniformity  
Each tablet was crushed and dissolved in 10 ml methanol.  The 
solution was filtered, diluted and the drug content was analyzed 
spectrophotometrically (Shimadzu, UV-1601) at 223nm.   
Dissolution Test: It was made by using USP Dissolution Tester 
and Apparatus Π (rotating paddle) with simulated saliva fluid 
(SSF) pH=6.75 kept at 37 μ 0.5ĈC . 
In vivo studies 
The study was carried out to compare the pharmacokinetics of 
(BH) from formulae B2 and  B7 to the reference  (Concor® 
tablets) following administration of a single dose  of BH (5mg) 
using  randomized, single dose, three-way crossover open-label 
study randomized crossover design (table no. 2). 
Subject Population: Six healthy Egyptian male volunteers (median 
age 28 years, median weight: 75 kg, median height: 180 cm) 
participated in this study. The volunteers underwent physical 
examination and complete hematological and biochemical 
examinations. None of the volunteers had any history of drug or 
alcohol abuse, nor did they have any acute or chronic 
gastrointestinal cardiac, vascular, hepatic or renal disease. No 
concurrent medication was allowed during the course of the study, 
and each subject read, understood and signed an informed 
written consent. All subjects were informed about the risks and 
objectives of the study. 
  Sample Collection: The drug was administered sublingual 
after overnight fasting and washout period of 1 week. Blood 
samples (5 mL) were collected into heparinized tubes at different 
time intervals: 0, 0.5, 1, 1.5, 2, 4, 6, 8, 12 and 24 h.  The blood 
samples were withdrawn into tubes washed with diluted heparin to 
guard against coagulation of blood. The blood samples were then 
centrifuged at 3000 rpm for 10 minutes and the clear plasma was 
then collected in polyethylene capped tubes and stored at -20ĈC 
till assayed. 
Table no. 2: Randomization plan of Bisoprolol Hemifumarate 
sublingual formulae (B2 and B7) viz. the conventional market 
(Concor®   5mg tablets, Amoun-Egypt)  
 
Volunteer 
Number Phase I Phase II Phase III 
1 B2 B7 Reference 
2 B7 B2 Reference 
3 Reference B2 B7 
4 B2 Reference B7 
5 B7 Reference B2 
6 Reference B7 B2 
 
Chromatographic conditions 
A modified HPLC method of analysis of Braza et al [14] for 
determination of  (BH)  in plasma was adopted. The HPLC 
apparatus consisted of: Isocratic pump LC-10 AS and a UV/VIS 
detector SPD-10A connected to a C-R6A Integrator (Shimadzu, 
Koyoto, Japan). The analytical column was Ponapak C18 HPLC 
column, 4.6 ï 250 I.D mm, particle size 125 ÀA (Waters 
Associates, Ireland).  The mobile phase consisted of acetonitrile 
and 0.01 M phosphate buffer pH 5.5 at a ratio (30:70) v/v.  The 
components of the mobile phase were mixed and adjust to pH 3 
using phosphoric acid then filtered through Millipore filter (0.45μm 
nylon membrane), the mobile phase was delivered at a flow rate 
of 2.0 ml min-1 and the detection wavelength was 223 nm. 
Chromatographic conditions 
A modified HPLC method of analysis of Braza et al [14] for 
determination of  (BH)  in plasma was adopted. The HPLC 
apparatus consisted of: Isocratic pump LC-10 AS and a UV/VIS 
detector SPD-10A connected to a C-R6A Integrator (Shimadzu, 
Koyoto, Japan). The analytical column was Ponapak C18 HPLC 
column, 4.6 ï 250 I.D mm, particle size 125 ÀA (Waters 
Associates, Ireland).  The mobile phase consisted of acetonitrile 
and 0.01 M phosphate buffer pH 5.5 at a ratio (30:70) v/v.  The 
components of the mobile phase were mixed and adjust to pH 3 
using phosphoric acid then filtered through Millipore filter (0.45μm 
nylon membrane), the mobile phase was delivered at a flow rate 
of 2.0 ml min-1 and the detection wavelength was 223 nm. 
 Pharmacokinetic analysis 
Pharmacokinetic parameters from plasma data following 
administration of the two formulae were estimated using, 
WinNonlin® (version 1.5, Scientific consulting, Inc., Cary, NC, 
USA).  Cmax (ng/mL) ,tmax (h) were the observed maximum drug 
concentration and the time needed to reach this concentration 
respectively. The area under the curve, AUC(0-24) (ng.h/mL) was 
calculated then the relative bioavailability (AUC test / AUC standard 
x100). The pharmacokinetic parameters were; Cmax, tmax, and 
AUC0ă24. 
Statistical analysis  
Statistical analysis was expressed as meanμ Standard deviation 
(SD) and  performed with t test for paired data using SPSS® 7.5 
for windows software.  The level of statistical significance was 
chosen as p ª 0.05.  
Results and Discussion 
Characterization of the solid complexes 
To confirm the existence of inclusion complexation of BH, HP-
ßCD, DSC and IR analyses were carried out. 
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Differential Scanning Calorimetry (DSC)  
Figure no.1 shows the DSC thermograms of BH, HP-ßCD, 
physical mixtures and the solid inclusion complexes in 1:1 molar 
ratio. The DSC thermogram of (BH) was a typical of the crystalline 
substance, exhibiting a sharp endothermic peak at 106.5 ĈC.  For 
HP-ßCD, it was observed a peak around 60ÀC corresponding to 
water loss and an endothermic peak at 333ĈC. 
It was clear that the sharp endothermic peak of the drug, around 
100ÀC became shorter in the thermograms of the physical 
mixtures that could be attributed to the reduced purity. On the 
other hand, the characteristic peak of the drug was totally 
disappeared in the complex thermogram. Similar results were 





Figure no. 1: DSC thermograms of: a) pure BH , b)Pure HP-β-CD, 
c)Physical mixture, d) Inclusion complex 
Fourier-transform infrared spectroscopy 
The IR spectra of BH, (BH/HP-ßCD), 1:1 physical mixtures and 
the inclusion complex, illustrated in figure no. 2.  BH shows its 
characteristic peaks at 2850-2450 cm-1 assigned for methyl 
group,  3200-3600 assigned ăNH and ăOH stretching, 3030 cm-1 
assigned to aromatic stretching, 1610 cm-1 for carbonyl group and 
1574 cm-1   for CH-NH-  group.   For HP-ßCD ,the spectra 
illustrate an intense broad absorption bands at 3500-3300 cm-1 
corresponding to the free ăOH stretching vibration [16] . The IR 
spectrum of the physical mixture shows the superposition of pure 
components spectra, indicating the absence of interaction 
between (BH) and HP-ßCD in the physical mixture. On the other 
hand, the IR spectra of (BH/ HP-ßCD) inclusion complex showed 
considerable differences when compared with those of the 
physical mixtures. The characteristic peaks of (BH) completely 





Figure no. 2:  FTIR patterns of: a) Pure Bisoprolol hemifumarate, 
b) Pure HP-β-CD, c) Physical mixture,  
d) Inclusion complex 
Evaluation of the sublingual tablets 
The weight uniformity test showed that none of the tablets 
deviated by more than 5%, indicating that all formulae fulfills the 
pharmacopoeial limits for weight variation.  In addition, the 
prepared tablets showed a uniformity of diameter and thickness; 
the values of tablets diameter were in the range of 8.00 to 8.13 
mm while the values of the tablets thickness were in the range of 
2.00 to 2.07 cm.  All formulae of the tablets were evaluated for 
various physical parameters which were reported in table no. 2.   
All the tablets maintained hardness in the range of 2.5 ă 4.6 
kg/cm2. The percent of friability was in the range of 0.41-0.92%. 
The drug content in different formulae was highly uniform and in 
the range of 95-102%. Regarding the disintegration time, it was 
noticed that the  formulae contain PEG 6000 result in prolongation 
of the disintegration time of tablets due to its binding effects[18]. 
The formulae B2 and B7 possessed the lowest disintegration time 
and wetting time due to the presence of the high concentration of 
chitosan (6%), which has some disintegration action so they were 
selected for in vivo study. Upon carrying out the dissolution test, it 
was observed that 100% of the drug was released three minutes 
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after the start of the dissolution run in all formulae. This was due 
to the water-soluble nature of the drug. Thus, the dissolution tests 
were not of value to the study. 
 












% of drug content 
μS.D. 
B1 3.3μ0.27 0.795 55.70μ8.22 48.94μ5.90 95.57μ3.19 
B2 4.6 μ0.48 0.405 17. 19μ2.89 24.9μ3.58 98.18μ2.65 
B3 3.8μ0.25 0.779 34.86μ4.98 39.19μ2.78 99.91μ2.15 
B4 2.8μ0.46 0.921 78.12μ9.63 69.94μ12.6
8 
101.58μ1.37 
B5 3.7μ0.81 0.779 49.27μ6.14 40.76μ4.25 102.47μ0.93 
B6 2.90μ0.49 0.891 119.39μ10.33 81.39μ6.31 99.33μ1.97 
B7 4.2μ0.36 00.55 24.25μ4.82 21.37μ2.86 98.44μ1.76 
B8 4.3μ0.21 0.611 69.35μ4.80 71.88μ9.26 102.57μ3.80 
 
Table no 4: Pharmacokinetic parameters μS.D of Bisoprolol hemifumarate following the administration of a single oral dose 






Concor® B2 B7 

















T ó (hr) 
 
10.234μ(1.57)  11.076μ(0.78) 9.825μ(1.28) 
Relative bioavailability  - 113.76% 106.794 
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Figure no. 4:  Plasma concentration of Bisoprolol Hemifumarate following the administration of Reference (Concor® tablet), B2 and B7 tablets.  
Data represent the mean values of n=6 μ S.D. 
 
Pharmacokinetics of Bisoprolol Hemifumarate from 
Sublingual tablets formulations 
Figure no.4   illustrates the mean concentrations of the drug 
following the administration of each formula, whereas table no.3 
gives the pharmacokinetic parameters of Concor ®, B2 and B7.  
The mean plasma concentration-time profiles for (BH) 5 mg tablet 
by sublingual and oral route show a comparable in time of 
occurrence of maximum plasma concentration (Tmax) for (BH)  
prepared formulae which were faster in sublingual route of 
administration when compared to oral route.  The mean Cmax 
estimated from B2 and B7 were 20.807μ2.48 ng/mL and 
19.617μ4.628ng/mL, respectively, while it was 17.862μ3.52 
ng/mL for Concor tablets.   The mean AUC0ă24 which reflects the 
total amount of drug absorbed over the 24 h time period for 
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h/mL, 308.315μ(17.95)ng h/mL and 289.318μ(28.37)ng h/mL  
respectively,  and  determined to be statistically significant 
different  (p < 0.05) for B2, while it was of non significant 
difference for B7.  The relative bioavailability of B2 and B7 were 
113.76% and 106.794% compared to Concor® tablets which 
taken as reference standard. 
The higher Cmax and faster tmax observed in both B2 and B7 than 
the reference conventional tablet (Concor®,Amoun-Egypt) may 
be attributed to the  rapid disintegration and drug absorption 
through the epithelium of sublingual membrane and consequently  
the bioavailability increased [20].   In addition the effect of  HP-
βCD  as incorporated product which have the ability to interact 
with macromolecules of sublingual membrane more efficiently, 
causing marked improvement in the drug sublingual absorption 
[21, 22] as illustrated in figure no.3.  The results of in vivo studies 
showed that formulation B2 containing 6%Chitosan, and 5% 
Crospovidone has the maximum Cmax and AUC and minimum 
tmax values. 
Based on the results of the present study, it can be concluded that 
the formulation of Bisoprolol hemifumarate 5 mg sublingual tablets  
Conclusion 
containing (BH) complexed with HP-βCD using appropriate 
excipients  seems to be a promising alternative formula to oral 
administration route  of Bisoprolol hemifumarate in acute 
management of angina pectoris and hypertension.
References 
 
[1]. Shojaei AH. Buccal mucosa as a route 
for systemic drug delivery: a review. J 
Pharm Pharm Sci., 1998. 1(1): p. 15-
30. 
[2]. Rajat Sharma MY. Formulation and 
Evaluation of Fast Disintegrating 
Sublingual Tablets of Glipizide: An 
Attempt to Treat Diabetic Coma. 
International Journal of ChemTech 
Research 2010. 2: 2026-2033. 
[3]. Sean C, and Sweetman A, "Martindale 
The Complete Drug Refrences" 35th 
edited by Phamaceutical Press, 2006. 
p875. 
[4]. Prichard BN. Bisoprolol: a new beta-
adrenoceptor blocking drug. Eur. Heart 
J. Suppl 1M., 1987. 121(9). 
[5]. Challa R, Ahuja  A, Ali  J, and Khar RK. 
Cyclodextrins in drug delivery: an 
updated review. AAPS PharmSciTech , 
Article 34, 2005. 6(2):  E329-E357. 
[6]. Nagarsenker MS, Meshram RN. Solid 
dispersion of hydroxypropyl beta-
cyclodextrin and ketorolac: 
enhancement of in-vitro dissolution 
rates, improvement in anti-inflammatory 
activity and reduction in ulcerogenicity 
in rats. J. Pharm. Pharmacol., 2000. 
52(8):949-956. 
[7]. Szejtli JS. Elimination of bitter, 
disgusting tastes of drugs and foods by 
cyclodextrins. Eur. J. Pharm. 
Biopharm, 2005. 61(3): 115-125. 
[8]. Szejtli J, Szente L. Elimination of bitter, 
disgusting tastes of drugs and foods by 
cyclodextrins. Eur J Pharm Biopharm, 
2005. 61(3): 115-125. 
[9]. Fu Y, Jeong SH, Kimura S, Park K. 
Orally fast disintegrating tablets: 
developments, technologies, taste-
making and clinical studies. Crit Rev 
Ther Drug Carrier Syst., 2004. 21: 433-
476. 
[10]. Nagarsenker  MS,  Joshi MS. 
Celecoxib-cyclodextrin systems: 
characterization and evaluation of in 
vitro and in vivo advantage. Drug Dev. 
Ind. Pharm., 2005. 31(2):169-178. 
[11]. Kottke MK, Rudnic EM. Tablet Dosage 
Forms, in Modern Pharmaceutics, G.S. 
Banker, and Rhodes  C.T., Editor. 
2002, Marcel Dekker Inc.: New York. p. 
437-511. 
[12]. Alderborn G. Tablets and compaction, 
in: Pharmaceutics the Science of 
Dosage Form Design, M.E. Aulton, 
Editor. 2002, Churchill Livingstone: 
Edinburgh. p. 397-439. 
[13]. Schiermeier S, Schmidt PC. Fast 
dispersible ibuprofen tablets. Eur J 
Pharm Sci, 2002. 15(3): 295-305. 
[14]. Braza AJ, Modamino PM , Lastrras CF, 
and Marino EL. Development 
,validation and analytical error fuction 
of two chromotagraphic methods with 
fluorimetric detection for the 
determination of bisoprolol and 
metoprolol in human. 
Biomed.Chromatogr., 2002. 16: 517-
522. 
[15]. Liu L and Zhu S. Preparation and 
characterization of inclusion complexes 
of prazosin hydrochloride with beta-
cyclodextrin and hydroxypropyl-beta-
cyclodextrin. J Pharm Biomed Anal, 
2006. 40(1): 122-127. 
[16]. Jun SW, Kim MS, Kim JS, Park HJ, 
Lee S, Woo S. and Hwang SJ. 
Preparation and characterization of 
simvastatin/hydroxypropyl-β-
cyclodextrin inclusion complex using 
supercritical antisolvent (SAS) process. 
. Eur. J. Pharm. Biopharm, 2007. 
66(3):413-421. 
[17]. Glomot F, Benkerrour L, Duchêne D, 
and Poelman M. Inclusion of retinoic 
acid in β-cyclodextrin Int. J. Pharm. , 
1989. 54(2): 175-179  
[18]. Leonardi D, Lamac MC, Salomn CJ. 
Development of prednisolone PEG 
6000 fast release tablets from solid 
dispersions: solid state 
characterization, dissolution behavior 
and formulation parameters. AAPS 
Pharm Sci Tech., 2007. 8(4 ):Article 
108. 
[19]. Mannila J, Järvinen T, Järvinen K, and 
Jarho P. Sublingual administration of 
Δ9-tetrahydrocannabinol/h-cyclodextrin 
Kharshoum et al. International Journal of Drug Delivery 4 (4) 484-491 [2012] 
 
PAGE | 491 |
 
complex increases the bioavailability of 
Δ9-tetrahydrocannabinol in rabbits. Life 
Sciences, 2006. 78: 911-1914  
[20]. Jacobsen J, Christrup L, and Jensen N. 
Medicated chewing gum: pros and 
cons Am J Drug Delivery, 2004. 2(2): p. 
75-88. 
[21]. Loftsson T, Jarho P, Masson M, and 
Jarvinen T. Cyclodextrins in drug 
delivery. Exp. Opinion Drug Del, 2005. 
2: 335-351. 
[22]. Senel S, Hincal A. Drug permeation 
enhancement via. buccal route: 
Possibilities and limitations. J. Control. 
Rel., 2001. 72:133-144.    
 
 
 
